Orchid Pharma Limited announced the outcome of its Board Meeting held on February 11, 2026. The Board approved the Unaudited Limited Reviewed Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025. The results were accompanied by the auditors’ limited review reports. The company also disclosed an exceptional item related to an incremental liability on past service cost due to revised ‘Labour Codes,’ amounting to ₹711.27 lakhs.
Board Meeting Outcome and Financial Period
Orchid Pharma Limited formally informed exchanges regarding the outcome of its Board Meeting, which commenced on February 11, 2026, at 01:30 P.M. (IST) and concluded at 05:15 P.M. (IST). The primary approval concerned the Unaudited Limited Reviewed Standalone & Consolidated Financial Results for the period ending December 31, 2025.
Key Financial Highlights (Standalone – Q3 FY2025 vs. Previous Periods)
Total Income for the quarter ended December 31, 2025 stood at ₹21,785.70 lakhs, compared to ₹22,727.97 lakhs in the previous year’s corresponding quarter. Total Expenses were marginally lower at ₹21,656.86 lakhs versus ₹20,337.34 lakhs previously. The Profit/(Loss) before tax for the quarter reflected a loss of (₹582.43) lakhs, a significant downturn from the previous profit of ₹2,390.63 lakhs.
For the nine months ended December 31, 2025, Total Income reached ₹61,566.56 lakhs, while Total Expenses amounted to ₹59,394.87 lakhs. The resulting Profit/(Loss) before tax was ₹1,460.42 lakhs, substantially less than the ₹7,863.47 lakhs reported for the same period in the prior year.
Exceptional Item Adjustment
An exceptional item of (₹711.27) lakhs was recorded in the standalone results for both the quarter and nine months ended December 31, 2025. This adjustment relates to an incremental liability arising from the management’s reassessment of employee benefits obligations following the consolidation of existing labour legislations into the unified ‘New Labour Codes,’ effective November 21, 2025.
Consolidated Performance Summary
On a consolidated basis, the Total Income for the quarter ending December 31, 2025 was ₹21,287.64 lakhs, against ₹21,734.25 lakhs year-on-year. The Profit/(Loss) before tax for the quarter resulted in a loss of (₹1,214.64) lakhs. For the nine months, consolidated Total Income was ₹60,155.14 lakhs, and the period concluded with a Profit/(Loss) before tax of (₹323.32) lakhs, contrasting sharply with the consolidated profit of ₹2,245.00 lakhs reported in the previous nine-month period.
QIP Utilization Update
The company provided an update on the utilization of funds raised via Qualified Institutional Placement (QIP). As of December 31, 2025, the total amount utilized stood at ₹33,256 lakhs out of the total proceeds of ₹39,454 lakhs received. The remaining balance of ₹6,198 lakhs was kept in fixed deposits, excluding interest earned.
Auditor’s Qualification Note
The auditors drew attention to the financial results of certain subsidiaries where they did not review the interim financial results. For three subsidiaries (Orchid Pharmaceuticals Inc. USA, Bexel Pharmaceuticals Inc., USA, and Diakron Pharmaceuticals, Inc. USA), the financial information reflecting nil revenue and nil net profit/loss was furnished by management and formed the basis for the conclusion regarding these specific components of the consolidated results.
Source: BSE
